Somewhat Positive Press Coverage Somewhat Unlikely to Impact Revance Therapeutics (RVNC) Share Price
News headlines about Revance Therapeutics (NASDAQ:RVNC) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Revance Therapeutics earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.4651167586506 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Insider Selling: Revance Therapeutics, Inc. (RVNC) CFO Sells 10,000 Shares of Stock (americanbankingnews.com)
- Insider Buying: Revance Therapeutics, Inc. (RVNC) Director Acquires 20,000 Shares of Stock (americanbankingnews.com)
- Analysts Anticipate Revance Therapeutics, Inc. (RVNC) Will Announce Quarterly Sales of $80,000.00 (americanbankingnews.com)
- FY2017 EPS Estimates for Revance Therapeutics, Inc. (RVNC) Reduced by Analyst (americanbankingnews.com)
- Brokerages Anticipate Revance Therapeutics, Inc. (RVNC) to Post -$0.94 EPS (americanbankingnews.com)
Shares of Revance Therapeutics (NASDAQ RVNC) traded up $1.10 during trading on Friday, reaching $26.80. The company had a trading volume of 228,700 shares, compared to its average volume of 173,872. Revance Therapeutics has a fifty-two week low of $15.85 and a fifty-two week high of $28.75.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.06). Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.05 million. During the same quarter in the prior year, the firm posted ($0.64) earnings per share. The company’s revenue was up .0% on a year-over-year basis. equities analysts anticipate that Revance Therapeutics will post -3.73 earnings per share for the current fiscal year.
A number of research firms have recently commented on RVNC. BidaskClub upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 target price on shares of Revance Therapeutics in a research note on Wednesday, September 6th. JMP Securities assumed coverage on Revance Therapeutics in a research note on Tuesday, August 22nd. They issued an “outperform” rating and a $34.00 price objective on the stock. Finally, Zacks Investment Research cut Revance Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 25th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $35.20.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Revance Therapeutics (RVNC) Share Price” was published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/11/11/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-revance-therapeutics-rvnc-share-price.html.
In other Revance Therapeutics news, CEO L Daniel Browne sold 7,600 shares of Revance Therapeutics stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $23.58, for a total transaction of $179,208.00. Following the completion of the transaction, the chief executive officer now owns 148,450 shares of the company’s stock, valued at approximately $3,500,451. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark J. Foley bought 20,000 shares of Revance Therapeutics stock in a transaction on Tuesday, November 7th. The shares were bought at an average cost of $26.96 per share, with a total value of $539,200.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $161,760. The disclosure for this purchase can be found here. Insiders sold a total of 59,226 shares of company stock worth $1,464,618 over the last 90 days. 18.86% of the stock is currently owned by company insiders.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.